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Abstract
The paper examines the development and use of lasers for cosmetic procedures. Given the lack of legal
and regulatory literature in this important and growing area, the sole focus of this author in writing the
paper is to highlight current dangers inherent in the widespread use of cosmetic lasers, as well as to raise
considerations that need to be addressed by the government and FDA vis-` a-vis the laser industry itself. The
use of lasers on the eye, which presents diﬀerent issues in and of itself, is not discussed except where it
reﬂects generally on the issues relating to cosmetic lasers, and is mentioned brieﬂy in this paper only for the
sake of completeness.
Part I provides an overview of the regulation of medical devices in the US; part II
discusses the use, development, and regulation of medical lasers in the cosmetic
industry, and part III details the dangers involved in the current practice of laser
treatment, as well as providing a critical overview of the laser industry itself.
From Creams to Lasers: Regulating the Beauty Industry in the
New Millennium
Aron Youngerwood (April 2002)
“Fashion is a form of ugliness so intolerable that we have to alter it every six months.”
- Oscar Wilde
1“They say God made humans in His image, and humans have been trying to repair the handiwork ever
since.”
- Tony Simmons, The News Herald 1
“Looking good is a sign of virtue. The body ...has become not only a window into the soul but an
expression of it.”
- Judith Gaines, The Boston Globe Magazine 2
“It’s been clear all along that with changing demographics and pressures to remain youthful, lasers have
the potential to penetrate the consumer market nearly as quickly as the beam of light they emit.”
- Pam Reynolds, The Boston Globe 3
INTRODUCTION: COSMETIC SURGERY TODAY 4
Where Aristotle once said that “beauty is the gift of God”, today it is the gift of cosmetic surgeons. In the
new millennium, we are increasingly treating our bodies like works of art, to be redesigned and sculptured
where nature and nurture have failed us. In our quest for youth and perfection, so much can be done to
alter the skin’s texture, color, shape and look that our body and face can be manipulated at will.
Cosmetic surgery, once considered within the exclusive domain of the rich and famous, has over the last few
decades been made available to the public at large, thanks to the advent of technology. No more is cosmetic
surgery considered a luxury, for now the bottom line when deciding on cosmetic surgery is not how much
will it cost you, but how much do your physical imperfections bother you.
The idea that you could let a total stranger permanently alter your face and body used to be generally
feared, but is now embraced. Traditionally cosmetic surgery involved days, if not weeks, of surgery, but
2Judith Gaines, Body Works, The Boston Globe Magazine, February 6, 2002.
3Pam Reynolds, Zapping Away The Years, The Boston Globe, June 11,1996, p.69.
4To avoid repetition, please note that all websites referenced in these footnotes were last visited between March 25 – 29
2002.
2today, many cosmetic procedures are over in an hour enabling you to have a quick transformation during
your lunch break. The factors that formerly made us reluctant to alter our appearance have disappeared –
no more do we accept ourselves just as nature made us; no more is vanity a sin; and no more is cosmetic
surgery an extravagant use of money5. Spas oﬀering cosmetic services are springing up as fast as Starbucks,
and with roughly the same clientele6.
While traditionally we relied on creams and herbs to cure our physical imperfections, today, thanks to
improved medical devices, we can perfect our face and body through such techniques as liposuction for fat
removal7; abdominoplasty (the “tummy tuck”) to remove excess wrinkled skin and fatty tissue from the
body8; breast surgery for the augmentation, reduction, and lifting of breasts9; chin and cheek augmentation
to improve the appearance of the chin10; laser resurfacing and dermabrasion11 to reduce and smooth scars;
rhytidectomy to lift the face and neck12; forehead lift to life the forehead skin and remove excess skin13;
hair transplants or replacement to help treat hair loss for both men and women14; otoplasty to correct
protruding ears15; sclerotherapy to remove spider veins, varicosities, broken capillaries or sunburst vessels16;
and, blepharoplasty to remove baggy eyelids 17.
Laser treatment is an exciting “futuristic” surgery. No instrument in medicine has the sex appeal of a laser,
or is surrounded by such an inordinate amount of hype. Patients think of it as a magical tool that will
somehow eliminate their cosmetic problem without pain18.
5For an excellent discussion of the psychology relating to cosmetic surgery, see ROBERT A. YOHO MD AND JUDY
BRANDY-YOHO RN, A NEW BODY IN ONE DAY: A GUIDE TO SAME-DAY COSMETIC SURGERY PROCEDURES,
Chapter 1 (1st ed. 1998).
6For an interesting discussion of the increasing cultural acceptance of cosmetic surgery, see Judith Gaines, Body Works, The
Boston Globe Magazine, February 6, 2002, where she addresses the question of “How did Americans, who two generations ago
rarely even pierced their ears, come to embrace all this cutting, sucking, and sanding of their ﬂesh?”
7According to the American Academy of Cosmetic Surgery, approximately 300,000 people a year had liposuction in the US
in the 1990s.
See http://www.cosmeticsurgery.org/procedures/liposuction.asp?mn=pc.
8For further information, see American Academy of Cosmetic Surgeons information sheets at
http://www.cosmeticsurgery.org/procedures/abdominoplasty tummy tuck .asp?mn=pc.
9See id. at http://www.cosmeticsurgery.org/procedures/breast surgery.asp?mn=pc.
10This is accomplished by inserting a small synthetic implant over the natural bone. See id. at
http://www.cosmeticsurgery.org/procedures/chin and cheek augmentation.asp?mn=pc.
11See http://www.cosmeticsurgery.org/procedures/laser surfacing and dermabrasi.asp?mn=pc.
12Id. at http://www.cosmeticsurgery.org/procedures/rhytidectomy face lift .asp?mn=pc.
13Id. at http://www.cosmeticsurgery.org/procedures/forehead lift.asp?mn=pc.
14Id. at http://www.cosmeticsurgery.org/procedures/hair replacement.asp?mn=pc.
15Id. at http://www.cosmeticsurgery.org/procedures/otoplasty ear surgery .asp?mn=pc.
16Id. at http://www.cosmeticsurgery.org/procedures/sclerotherapy vein surgery .asp?mn=pc.
17See the Cosmetic Eyelid Resource Guide at http://www.cosmetic-eyelid-surgery-resource.info/.
18See Barry A. S. Lycka, Shaping a New Image: The Practice of Cosmetic Surgery, Chapter 13 (1st ed. 1999).
3Today, in our consumer-driven and time-demanding culture, for many, life is about ﬁnding the quickest and
easiest way to do something. In fact, many medical treatments that currently exist are geared towards
youthifying individuals quickly. Whether trying to regrow hair (Propecia), gain an erection (Viagra) or
lose weight (Fen-Phen) people are incredibly willing to open their wallets and subject themselves to some
questionable treatments in order to regain a part of their youth without properly evaluating the pros and
cons of such treatment19.
This paper examines the development and use of lasers for cosmetic procedures. Given the lack of legal
and regulatory literature in this important and growing area, the sole focus of this author in writing this
paper is to highlight current dangers inherent in the widespread use of cosmetic lasers, as well as to raise
considerations that need to be addressed by the government and FDA vis-` a-vis the laser industry itself. The
use of lasers on the eye, which presents diﬀerent issues in and of itself, is not discussed except where it
reﬂects generally on the issues relating to cosmetic lasers, and is mentioned brieﬂy in this paper only for the
sake of completeness.
Part I provides an overview of the regulation of medical devices in the US; part II discusses the use, devel-
opment, and regulation of medical lasers in the cosmetic industry, and part III details the dangers involved
in the current practice of laser treatment, as well as providing a critical overview of the laser industry itself.
I. MEDICAL DEVICE REGULATION IN THE US
A. Overview
The U.S. Food & Drug Administration (“FDA”20) currently regulates the manufacture and marketing of
medical devices in the United States under the Federal Food, Drug and Cosmetic Act21 (“FDCA”). In 1976,
19See Michael J.Ward, The History and Controversial Future of Refractive Surgery, SURE Program (1999) (available at
http://www.sciencenet.emory.edu/undergrad/SURE/Articles/1999 art ward.html).
20See <http://www.fda.gov/> for an overview of the FDA.
2121 U.S.C. 301 et seq. It was not until 1938, that medical devices were subject to federal regulation. However, even after
this law, the degree of regulation was generally perceived as unsatisfactory, thereby entailing further amendments in 1976, 1990,
4partly in response to the widely-publicized IUD and pacemaker failures, Congress passed the Medical Device
Amendments22 (“MDA”) giving the FDA broad authority over medical devices. The new law also required
that in most cases marketing of a device could not legally begin until the FDA ﬁnds that the device is safe
and eﬀective. The law was most signiﬁcantly amended in 1990 by the Safe Medical Devices Act (“SMDA”)23;
in 1992 by the Medical Device Amendments24 and, yet again in 1997 by the Food and Drug Administration
Modernization Act (“FDAMA”)25 to further expand the FDA’s authority, increase its enforcement powers,
and require device manufacturers and others to report adverse device experiences to the FDA.
The main changes introduced by this new device regulatory framework included the following:
(1) devices would now be classiﬁed into three distinct classes based on their perceived risk to
patients; (2) a premarket notiﬁcation system was introduced to enable the FDA to assess the
safety and eﬀectiveness of products prior to marketing; and (3) a premarket approval system,
distinct from the New Drug Premarket Approval requirements for drugs, was introduced for
high-risk devices.
B. FDA Classiﬁcation of Devices26
The MDA of 1976 required the FDA to classify all devices into one of three regulatory control categories,
depending on the degree of regulation necessary to provide reasonable assurance of the device’s safety and
eﬀectiveness. Under the classiﬁcation provisions, all products marketed prior to implementation of the 1976
MDA were categorized by a series of advisory committees.
1992, and 1997 which led to the establishment of a comprehensive system of reviewing and approving the marketing of medical
devices in the US.
22Pub. L. No. 94-295, 90 Stat. 539 (codiﬁed at 15 U.S.C. Sec.55 (1994); 21 U.S.C. Sec.31, 331, 334, 351, 352, 358, 360, 360c-k,
374, 379, 379a, 381). The MDA incorporated the recommendations of the Study Group on Medical Devices, Medical Devices:
A Legislative Plan. (U.S. Dept. of Health, Education, and Welfare 1970), generally referred to as the ‘Cooper Committee’.
23Pub. L. No. 101-629, 104 Stat. 4511 (codiﬁed at 21 U.S.C. Sec. 301 note, 321, 333, 333 note, 351, 353, 360, 360c, 360c
note, 360d-i, 360i note, 360j, 360j note, 3601, 360gg-hh, 360hh note, 360ii-ss, 383, 383 note; 42 U.S.C. §§ 263b-n (1994)).
24Pub. L. No. 102-300, 106 Stat. 238 (codiﬁed at 21 U.S.C. Secs 301 note, 321, 331, 334, 346a, 352-353, 356-357, 360c-d,
360g-i, 360i notes, 3601, 360mm, 371-372, 372a, 376, 381; 42 U.S.C. Sec 262).
25Pub. L. No. 105-115, 111 Stat. 2296 (1997), as amended 21 U.S.C. Secs 301-394 (1997)).
26For a more comprehensive overview of this area, see PETER B. HUTT & RICHARD A. MERRILL, FOOD AND DRUG
LAW CASES AND MATERIALS pp.742-792 (2nd ed. 1991); Robert Higgs, Wrecking Ball: FDA Regulation of Medical Devices,
Policy Analysis No. 235 (August 7, 1995); William F. Pritchard & Ronald F. Carey, Primer on Medical Device Regulation:
U.S. Food and Drug Administration and Regulation of Medical Devices in Radiology, 205 RADIOLOGY 27 (1997); Lee H.
Monsein, Primer on Medical Device Regulation, Part II: Classiﬁcation, 205 RADIOLOGY 1, (1997); John J. Smith, Physician
Modiﬁcation of Legally Marketed Medical Devices: Regulatory Implications Under the Federal Food, Drug, and Cosmetic Act,
55 Food & Drug L.J. 245; and Rodney R. Munsey, Trends and Events in FDA Regulation of Medical Devices Over the Last
Fifty Years, 50 Food & Drug L.J. 163.
5Class I devices27, considered relatively safe and low-risk to patients, are only subject to general
controls designed to achieve safety and eﬀectiveness through control of manufacturing, labeling
and related issues28 including FDA’s Good Manufacturing Practices (GMP)29. Examples of
Class I devices include bandages, x-ray grids30, breath alcohol tests31, and manual and electric
toothbrushes32. Devices under this class are generally regulated by device type33. Class I
devices, unless speciﬁcally exempted by regulation, must also be cleared by the FDA prior to
marketing through a premarket notiﬁcation ﬁling 34.
Following the FDAMA (which amends the FDCA), most Class I and certain low risk Class II devices are
exempt from the pre-notiﬁcation requirement35. All other devices are still subject to the notiﬁcation
requirement36.
A premarket Notiﬁcation ﬁling must be submitted to the FDA before a manufacturer can market its device
in the United States, or before any signiﬁcant changes are made to an existing device that could signiﬁcantly
aﬀect the safety or eﬀectiveness of the device or would be a major change or modiﬁcation in the intended
27Deﬁned as products that are not purported or represented to be for a use that is of substantial importance in preventing
impairment of human health, and that do not present a potentially unreasonable risk of patient injury (FDCA § 513(a)(1)(A)(ii)
(21 U.S.C. § 360c(a)(1)(A)(ii)).
28General controls include: prohibition against adulteration and misbranding (FDCA §§ 501 and 502); banned devices (§
516); notiﬁcation, repair, and replacement or refund (§ 518); records and reports (§ 519); and restricted devices (§ 520). Unless
speciﬁcally exempted by regulation, general controls contain requirements for device manufacturers or other designated persons
to: (i) register their establishment with FDA; (ii) list their devices with FDA; (iii) comply with labeling regulations in 21
C.F.R. pts. 801, 809, or 812; (iv) submit a premarket notiﬁcation to FDA; and (v) design and produce devices under good
manufacturing practices. See generally Lee H. Monsein, Primer on Medical Device Regulation, Part II: Classiﬁcation, 205
RADIOLOGY 2 (1997); Rodney R. Munsey, Trends and Events in FDA Regulation of Medical Devices Over the Last Fifty
Years, 50 Food & Drug L.J. 163, 166 (1995); CDRH, FDA, Device Advice (see www.fda.gov/cdrh/devadvice).
29The FDA’s Good Manufacturing Practices (GMP) regulation requires all domestic and foreign manufacturers of medical
devices (except certain exempted Class I devices) that are commercially distributed in the United States to have in place
a quality assurance program. Adequate speciﬁcations and controls must be established and ﬁnished devices must meet these
speciﬁcations. The FDA may periodically inspect the operations and records of domestic and foreign manufacturers to determine
compliance with the GMP regulation.
The GMP regulation covers the methods, facilities, record-keeping (such as complaint, device master-record, and production
history ﬁles), and controls used in manufacturing, packaging, labeling, inspecting, storing, and installing medical devices. All
devices must meet general GMP requirements, but critical devices must meet additional GMP requirements.
3021 CFR 892.6500.
3121 CFR 862.3050.
3221 CFR 872.6855, 872.6865.
33Under the FDAMA §510(l), most Class I devices are § 510(k) exempt. However, even when such devices are subject to
the 510(k) process, they are regulated by the type of medical product, though they are approved individually. In contrast, a
Class III device that is subject to a premarket approval application (PMA) is subject to general controls and, depending on
the novelty of the device, a unique set of regulatory controls.
34See id.
35FDAMA § 206.
36i.e. nonexempt Class I and II devices, and Class III devices, are subject to the premarket notiﬁcation requirement.
6use of the device.
The general controls discussed above are relevant for all types of devices and also apply to devices in Classes
II and III.
Class II devices which present a greater risk of injury to the patient than class I devices must comply with
both the general controls discussed above, as well as certain “special controls”37 which may be established
by FDA regulation. Class II devices are also subject to the premarket notiﬁcation procedures38. Examples
of Class II devices include oxygen masks39; artiﬁcial eyes40 and, other devices that do not by themselves
maintain life, such as cardiac monitors.
Class III devices are deﬁned as those used for “supporting or sustaining human life or for a use which
is of substantial importance in preventing impairment of human health” or those devices that “present a
potentially unreasonable risk of illness of injury”41. Given that such devices entail the most signiﬁcant risks,
in addition to meeting the above requirements, they must also be shown to be safe and eﬀective before being
marketed. Class III devices are therefore subject to a premarket approval (“PMA”) process by which the
FDA reviews clinical evidence as to the safety and eﬀectiveness of the device before granting approval for
the device to be marketed or manufacturered42. Examples of Class III devices include replacement heart
valves43 and extended wear contact lenses 44.
Medical lasers, depending on their application, are usually categorized in Class II or III 45. Manufacturers
can, however, request a reclassiﬁcation from the FDA46.
The MDA further distinguishes between those devices legally marketed before implementation of the leg-
37An example of such controls include performance standards (if adopted by the FDA) requiring the device to meet certain
functional characteristics (the FDA has been notoriously lax in adopting such standards); postmarket surveillance; patient
registries; development and dissemination of guidelines; recommendations; and other appropriate actions. In the absence of any
special controls established by regulation, only general controls apply to class II devices. See FDCA §513(a)(1)(B) (21 U.S.C.
§ 360c(a)(1)(B)(ii)).
38As with Class I devices, Class II device are evaluated individually under § 510(k) (if applicable), and then regulated by the
type of medical product. See supra note 33
3921 CFR 868.5580.
4021 CFR 886.3200.
41See FDCA §513(a)(1)(C)(ii) (21 U.S.C. §360c(a)(1)(C)(ii)).
4221 U.S.C. §360e(b).
4321 CFR 870.3925.
4421 CFR 886.5925.
45The Gray Sheet, Vol.12, No. 46, pp. 9-11 (available at http://www.fdcreports.com/grayout2.shtml -Subscription required.
4621 C.F.R. Sec. 860.123.
7islation in May 1976 (pre-1976 devices) and those marketed after that date (post-1976 devices). Pre-1976
Class III devices can continue to be legally marketed until FDA requests data (clinical or otherwise) that
demonstrates safety and eﬀectiveness47. Any new device after 1976 is automatically treated as a Class III
device, and must go through the PMA process requiring demonstration of reasonable assurance of safety and
eﬀectiveness48 before it may be marketed in the United States.
However, by way of an exception, certain Class III devices that are “substantially equivalent” to a pre-1976
device will be placed in the class of its “predicate” product49 and may be marketed immediately, subject to
existing regulations imposed on the predicate product.
C. Substantial Equivalence
Since the PMA process is time-consuming and expensive, most manufacturers generally attempt to avoid
it by claiming their device is “substantial equivalent” to a “predicate” (pre-1976) device. If this is the
case, the new device will be placed in the predicate’s class and can be marketed immediately subject to
any regulations applicable to the predicate device. As one commentator has noted: “510(k) submission has
become the option of choice for bringing a new device to market”50. However, devices without predicates
and not judged to be substantially equivalent to a pre-1976 device, are placed automatically in Class III and
are subject to the PMA process.
The term “substantial equivalence”, although originally undeﬁned and left to the interpretation of the FDA51,
was eventually deﬁned in the SDMA of 1990. A device is “substantially equivalent” if, in comparison to a
predicate device it (1) has the same intended use and technological characteristics52 as the predicate device;
or (2) has diﬀerent technological characteristics that do not raise new questions of safety and eﬀectiveness,
and the manufacturer demonstrates that the device is as safe and eﬀective as the legally marketed device53.
47See id. § 360c(a)(1)(C)(ii) (FDCA § 513(a)(1)(C)(ii)).
48See 21 U.S.C. § 360c(a)(1)(C) (FDCA § 513(a)(1)(C)).
49See § 360c(f)(1)(A)(ii) (FDCA § 513(f)(1)(A)(ii)).
50Jonathan S. Kahan, Premarket Approval Versus Premarket Notiﬁcation: Diﬀerent Routes to the Same Market, 39 Food
Drug Cosm. L.J. 510, at 514 (1984) (Hereinafter “Kahan, Premarket Approval etc”).
51See PETER B. HUTT & RICHARD A. MERRILL, FOOD AND DRUG LAW CASES AND MATERIALS pp.754-756
(2nd ed. 1991).
52For the purpose of this deﬁnition, the term diﬀerent technological characteristics means that when compared to the predicate
device it can be shown that there is a signiﬁcant change in the materials, design, energy source, or other features of the device
from those of the predicate device. See CDRH Device Advice at: http://www.fda.gov/cdrh/devadvice/.
5321 U.S.C. §360c(i). See CDRH Device Advice at: http://www.fda.gov/cdrh/devadvice/. Detailed information on how
8Once the device is determined to be substantial equivalent, it can then be marketed in the U.S and is
generally subject to the same regulatory requirements as its predicate54. However, if FDA determines that a
device is not substantial equivalent, the device is placed in Class III and must go through the PMA process
(alternatively, the applicant may resubmit another 510(k) with additional data, petition for reconsideration
or reclassiﬁcation, or seek judicial review55).
Signiﬁcantly, prior to the 1990 amendments, the FDA did not generally require human clinical trials in
determining substantial equivalence 56. However, following the 1990 amendments, the FDA were given
express authority to require the submission of performance data, including data from clinical trials, in order
to make a substantial equivalence determination57.
Furthermore, in addition to this lack of a mandatory requirement for clinical human testing, the introduction
of “piggybacking”, a process that allowed post-1976 devices judged substantially equivalent to pre-1976
devices to serve as predicates themselves 58, made it even easier for manufacturers to market their products
and avoid the FDA PMA process. The signiﬁcance of this applies particularly to cosmetic lasers (as will be
discussed later) given that laser manufacturers are able to avoid the more demanding premarket approval
process by making incremental changes to the lasers and relying on the substantial equivalence procedure to
obtain marketing approval.
It should further be noted that the legislative history of substantial equivalence reveals that the introduction
of the concept was not to insure safety and eﬀectiveness, but rather was a concession to industry to treat pre-
and post-amendment devices equally 59. Indeed, the eﬀect of the introduction of the substantial equivalence
FDA determines substantial equivalence can be found in the Premarket Notiﬁcation Review Program 6/30/86 (K86-3) blue
book memorandum at: http://www.fda.gov/cdrh/k863.html. The FDAMA made some amendments to the legislative deﬁ-
nition of substantial equivalence, which are discussed below. e.g. enabling the CDRH to request clinical data as part of the
substantial equivalence determination, but limiting the type of data requested to the “least burdensome” data needed to deter-
mine substantial equivalence – therefore information not directly relevant to substantial equivalence, e.g. information regarding
absolute safety and eﬀectiveness of a device, may not be requested.
54Although with individually regulated Class III devices, the situation is more complicated. If the predicate is a pre-1976
device for which the FDA has not requested safety and eﬀectiveness data, the new device may be marketed legally after
the product has received §510(k) clearance (see John J. Smith, Physician Modiﬁcation of Legally Marketed Medical Devices:
Regulatory Implications Under the Federal Food, Drug, and Cosmetic Act, 55 Food & Drug L.J. 245).
55See id.
56See John J. Smith, Physician Modiﬁcation of Legally Marketed Medical Devices: Regulatory Implications Under the Federal
Food, Drug, and Cosmetic Act, 55 Food & Drug L.J. 245.
57See 21 U.S.C. §360c(i)(1)(A)(ii)(I). See id.
58See supra note 56.
59See SUBCOMM. ON OVERSIGHT & INVESTIGATIONS OF THE HOUSE COMM. ON ENERGY & COMMERCE,
LESS THAN THE SUM OF ITS PARTS: REFORMS NEEDED IN THE ORGANIZATION, MANAGEMENT, AND RE-
SOURCES OF THE FDA’S CENTER FOR DEVICES AND RADIOLOGICAL HEALTH, H.R. REP. NO. 103-N, at 60 (1993)
9requirement was to enable manufacturers to evade the more stringent PMA requirements giving them a
fast-track for getting their products on the market60. A 1988 General Accounting Oﬃce report stated that
of the 36,000 medical devices marketed after FDA review, only 6% went through the PMA process while the
other 94% went through the substantial equivalence procedure61. Furthermore, the FDA rarely found that
a new device was not substantially equivalent to a predicate device selected by the applicant. The rejection
rate was approximately 2% 62.
Criticism arose as to use of the substantial equivalent test for deciding whether a device should be marketed,
especially given the fact that the test did not focus on the most relevant question, namely is the device
safe and eﬀective? Instead, the test focuses on a secondary question, namely, is the device substantially
equivalent to a pre-enactment device with regards to safety and eﬀectiveness63? Furthermore, there was
general criticism of CDRH’s unoﬃcial policy to reject only 2% of 510(k) applications which “encouraged
approvals in all but the most obviously deﬁcient 510(k) applications.”64
The FDAMA addressed the issue of delays in premarket notiﬁcation review time65, and the need to speed
up the introduction of new technologies. An important FDAMA provision required the FDA to consider
only the “least burdensome means” of evaluating eﬀectiveness that would have a reasonable likelihood of
resulting in approval66. The FDAMA amended the deﬁnition of substantial equivalence by enabling the
CDRH to request clinical data as part of the substantial equivalence determination, but limiting the type
(“LESS THAN SUM OF ITS PARTS”); and David A. Kessler et al., The Federal Regulation of Medical Devices, 317 New Eng.
J. Med. 357, at 359 (1987) (“The decision to include a ‘substantial equivalence’ provision in the statute was made to ensure
fair treatment of post-amendment devices”).
60See supra note 50, Kahan, Premarket Approval etc, at 510 (“The proof is in the numbers: in calendar year 1977, the ﬁrst
full year under the Amendments, [FDA] received 2433 requests to allow marketing of new devices. Only 11 of those invoked
the [PMA] mechanism ...FDA projects that in ...1985 it will review only 95 PMAs, while during the same period it expects
to review 5200 notiﬁcations under the 510(k) mechanism.”)
61GENERAL ACCOUNTING OFFICE, MEDICAL DEVICES: FDA’S 510(K) OPERATIONS COULD BE IMPROVED,
PEMD-88-14, at 2 (1988)
62See supra note 50, Kahan, Premarket Approval etc, at 515-6 (rate of rejection form 1976-1983).
63Richard M. Cooper, Clinical Data Under Section 510(k), 42 Food Drug Cosm. L.J. 192 (1987), at 199-200 (“Richard Cooper
etc”).
64LESS THAN SUM OF ITS PARTIS, supra note 59, at 37-8 (revealing that 2% was considered to be the “acceptable
rejection rate” and that a ﬁnding of no substantial equivalence by a reviewer was subject to more scrutiny by supervisors than
a ﬁnding of substantial equivalence).
65According to the Senate Report, prior to the implementation of the FDAMA (See S. REP. No. 105-43, at 20 (1997)),
premarket notiﬁcation classiﬁcation review time increased 100% between 1990 and 1996, despite the number of applications
remaining steady. Time for premarket approvals more than doubled in the same time period, although submissions dropped by
nearly half.
66See 21 U.S.C. § 360c (a)(3)(D)(ii) (FDCA § 513(a)(3)(D)(ii); FDAMA § 205). See John J. Smith & Anne M. Shyjan,
Deﬁning Least Burdensome Means Under The Food And Drug Administration Modernization Act Of 1997, 55 Food & Drug
L.J. 435.
10of data requested to the “least burdensome” data needed to determine substantial equivalence – therefore
information not directly relevant to substantial equivalence, e.g. information regarding absolute safety and
eﬀectiveness of a device, may not be requested67. Thus, the Senate report, prior to the implementation of
the FDAMA, stated that the FDA “must ask for the least burdensome type of valid scientiﬁc evidence that
will meet Congress’ criteria for eﬀectiveness.”68
This drive for eﬃciency so as to ease the process by accelerating device approval, as well as to reduce the
cost for private companies to get their products on the market was, in this writer’s opinion, to the detriment
of the public welfare in terms of proper assessment of device safety and eﬀectiveness, even though supporters
of the FDAMA stated that this improved patient access to important new technologies.
A further development introduced by the SMDA and the Medical Device Amendments of 1992 was the
requirement for users (i.e. manufacturers, distributors, hospitals and clinics) to report to FDA any deaths or
serious injuries caused by a device. Annual reports of such events to the FDA also are mandated. However,
by narrowing it to only reporting of “serious injuries”, severely limits post-market surveillance of devices like
lasers, which have the capacity for causing injury but on a more moderate level69.
However, the position with substantial equivalence remains very much the same with the FDA requiring
submission of clinical data for only a small percentage of 510(k) applications, and, in complying with the
“least burdensome means” test to establish substantial equivalence, pre-clinical data is generally considered
satisfactory for most applications70.
D. Investigational Device Exemptions
Another route used by device manufacturers is the Investigational Device Exemption (IDE) (or an exemption
from the IDE regulations themselves, such as for certain diagnostic or custom devices) which permits clinical
study of unapproved devices (or study of new uses for approved devices). The exemption in an IDE is from
certain regulatory requirements that would otherwise apply to such a device, such as PMA, performance
67See 21 U.S.C. §360c(i)(1)(D); and Richard Cooper etc at supra note 63.
68S. REP. NO. 105-43, at 25 (1997)
69See 21 U.S.C. §360i(b) and §360(i)(a)(3).
70See CDRH Device Advice: Premarket Notiﬁcation [510(k)], at:
http://www.fda.gov/cdrh/devadvice/314.html#link 2.
11standards, and GMP regulations, though an eﬀective quality assurance system must be in place that, in
anticipation of premarket approval by the FDA, should be based on or exceed the GMP requirements.
Extensive record-keeping, reporting, and monitoring of the clinical studies is also required.
E. Special Issues For Radiation-Emitting Devices
Particularly pertinent for lasers, any device that emits radiation must additionally comply with the Radiation
Control for Health and Safety Act passed in 196871 which is also administered by the FDA and which
authorizes the development of performance standards and general controls for ionizing radiation products.
The Act was designed to protect the public from the dangers of electronic product radiation. Devices
that either intentionally emit radiation (such as x-ray equipment) or emit radiation as a consequence of their
operation (such as CRTs and television sets) are covered. Furthermore, certain light-emitting products, which
emit intense, directed radiation, such as lasers72, sunlamps73,and ultraviolet lighting74 are also covered. In
addition to speciﬁc emissions standards, and to prevent unnecessary exposure to such radiation due to the use
of these products75, manufacturers and distributors of products meeting the deﬁnition of electronic product
radiation76 are required to comply with certain formalities, for example, record keeping, speciﬁc labeling
requirements, and reporting to the Center for Devices and Radiological Health (“CDRH”)77.
II.
LASERS IN COSMETIC SURGERY: ONE SMALL WRINKLE FOR MAN, ONE GIANT STEP FOR MANKIND.
7142 U.S.C. Sec. 263b.
72For performance standards for lasers, see 21 CFR 1040.10 and 1040.11. In determining the applicable reporting category
for a laser product, the CDRH bases its decision on the worst-case hazard present within the laser product.
73For an overview of the regulation of tanning salons in the US, see Leigh R. Fraser, Should Tanning Salons Be Banned? (1995),
Unpublished, but stored at Harvard Law School’s Food & Drug Law Archives held by Peter Hutt (email: phutt@cov.com).
74Other examples of radiation emitting electronic products subject to the provisions of the FDCA and therefore regulated by
FDA are listed in 21 CFR 1000.15.
75For an overview of this area, see CDRH Device Advice on products emitting radiation at:
http://www.fda.gov/cdrh/devadvice/311.html; and PETER B. HUTT & RICHARD A. MERRILL, FOOD AND DRUG
LAW CASES AND MATERIALS pp.794-805 (2nd ed. 1991).
76FDCA §531.
77The ﬁnal regulations are contained in 21 CFR 1000- 1299.
12A. Overview
Over the last decade, lasers have gradually been transformed from a ﬁgment of science ﬁction to a powerful
medical tool for surgeons and dermatologists in the ﬁght for skin perfection. In this short time span, medical
lasers have been used for removal of birthmarks (port wine stains), moles, tattoos, acne scars and other
blemishes. Lasers are also used for a growing number of other cosmetic procedures including hair removal,
treatment of wrinkles, and tooth whitening78.
Indeed, according to the American Academy of Cosmetic Surgery in Chicago, nearly 170,000 Americans
underwent laser resurfacing of the face in 1998, which is approximately twice the number of the more
traditional surgical facelifts performed in the same year79.
Compared to traditional surgical tools, lasers oﬀer signiﬁcant advantages. First, unlike a knife or scalpel, a
laser can cut through tissue without causing excessive bleeding. In fact, lasers can actually coagulate tissue
to stop bleeding – something which a knife cannot do80. Second, lasers can reach or impact areas of the body
more easily than with a scalpel, a fact that is today increasingly important with many internal procedures.
Third, lasers are more precise, enabling surgeons to pinpoint the laser light on a speciﬁc area, such as a mole
or hair follicle, without aﬀecting the neighboring tissue81. Precision is vital when it comes to invasive or
cosmetic surgery.
B. What is a Laser?
The term ‘laser’ is an acronym for ‘Light Ampliﬁcation by Stimulated Emission of Radiation’. Put simply, a
laser tool emits a beam of light which, when focused on the skin, will “vaporize” its target 82. This is made
possible because of the way lasers interact with electrons. The beam of light is sensitive to diﬀerent colors
thereby allowing lasers to remove colored or pigmented areas on the skin, such as brown spots (known by
78See CDRH, Laser Facts, May 2001 at: http://www.fda.gov/cdrh/consumer/laserfacts.html.
79Alexandra Greeley, FDA Consumer, May-June 2001.
80See id.
81See id.
82ROBERT A. YOHO MD AND JUDY BRANDY-YOHO RN, A NEW BODY IN ONE DAY: A GUIDE TO SAME-DAY
COSMETIC SURGERY PROCEDURES, Chapter 14 (1st ed. 1998) (hereafter “A NEW BODY IN ONE DAY”).
13dermatologists as caf´ e-au-lait marks) and tattoos83.
There are many diﬀerent types of lasers, some designed to remove discolorations and other imperfections
on the skin, whilst others designed for resurfacing the skin by vaporization of the skin’s upper layer84. It
is beyond the scope of this paper to attempt to describe the many diﬀerent kinds of lasers available, and
therefore the descriptions in this paper are conﬁned to the essential basics.
C. Common Cosmetic Uses for A Laser: Quick Fixes To Old Problems
1. Wrinkles and Scars - Skin Resurfacing
Prior to lasers, there were few safe and eﬀective solutions to help remove or improve wrinkles or scars
(caused by acne, chicken pox or trauma), as well as for improving the appearance of photo damaged skin.
Dermabrasion was one often-used solution. This involves using a tiny electric sander revolving at high
speeds which literally “sands” the surface of the skin thereby removing or reducing wrinkles and scars.
However, dermabrasion produces signiﬁcant bleeding, and scarring is common85. Another solution, acid
peeling, which, rather than sanding the skin surface, applies one of two acids86 to produce an injury to
the old skin. Unfortunately, permanent color loss occurs in most cases with patients often ending up with
a white patch on their faces87, and some patients experiencing scarring. Despite this, superﬁcial or light
trichloracetic (TCA) peels, are generally successful with very low concentrations of TCA being used on the
face for minor skin complaints88.
Lasers have superseded these two solutions by introducing an arguably safer and more predictable procedure
to remove wrinkles and facial scars89. Laser resurfacing oﬀers a number of advantages over other resurfacing
methods: precision, little (if any) bleeding; less post-operative discomfort90; and allowing more accurate
83See id.
84For more information on how a laser works, see the Lawrence Livermore National Laboratory (a U.S. Department of Energy
national laboratory operated by the University of California) website at:
http://www.llnl.gov/nif/library/aboutlasers/how.html.
85See supra note 82, A NEW BODY IN ONE DAY, Chapter 5. See also the Plastic Surgery Information
Service at http://www.plasticsurgery.org/surgery/dermabra.htm; and the Cosmetic Surgery Education Center at
http://www.dryoho.com/.
86Usually phenol or trichloracetic (TCA). See id.
87See supra note 85, A NEW BODY IN ONE DAY.
88See id.
89Iain McKay FRCS, Laser Skin Resurfacing, Skinlaser Directory (produced by the Disﬁgurement Guidance Centre in the
UK) available at: http://www.skinlaserdirectory.org.uk/resurfacing.htm).
90See Plastic Surgery Information Service at http://www.plasticsurgery.org/surgery/lasersrg.htm.
14depth control with distinct color changes in the skin91.
Laser resurfacing is a controlled burning procedure during which the laser vaporizes superﬁcial layers of
facial skin (generally the epidermis and papillary dermis92), removing not only wrinkles and lines, but also
acne scars, folds and creases around the nose and mouth. Eﬀectively, the laser resurfacing creates a fresh
surface over which new skin can grow93.
An explanation of the procedure is provided by Dr. Robert Yoho:
“The laser zaps small areas on the face as the doctor moves carefully from one area to the next, treating
each in turn, making sure to blend everything evenly. In the past, lasers could only work on very small spots,
about an eighth of an inch at a time. But now, the technology has improved to the point where we can laser
spots about 1.5 centimeters (about two-thirds of an inch) in diameter, using a laser pattern generator....
The laser doesn’t actually burn the skin, because there’s very little heat transfer involved. Instead, it vaporizes
the skin surface by making the water boil inside the skin. During the process, the treated skin changes in a
way that allows the doctor to wipe oﬀ the top layers with a wet gauze pad. With each zap of the laser, the
doctor can see new, fresh skin appear. Almost no bleeding occurs. Each laser zap lasts a fraction of a second
...The whole process lasts about an hour ....” 94
Carbon Dioxide (“CO2”) and Erbium95 lasers are the two lasers generally used in laser resurfacing, each,
with diﬀerent eﬀects.
Several manufacturers have received FDA clearance to advertise their lasers for the treatment of wrinkles,
while others may claim skin resurfacing more generally.
Overall, as one surgeon notes:
91See id.
92although for deeper resurfacing, the upper levels of the reticulas dermis is also removed. See Plastic Surgery Information
Service at http://www.plasticsurgery.org/surgery/lasersrg.htm.
93See supra note 82.
94See supra note 82, A NEW BODY IN ONE DAY, chapter 5. See also Iain McKay FRCS, Laser Skin Resurfacing, Skinlaser
Directory (produced by the Disﬁgurement Guidance Centre in the UK): “All patients will have a raw, weeping, uncomfortable
superﬁcial burn for about one week...skin erythema (redness) will last for 5 weeks to 6 months depending on which laser is
used, the depth of injury and individual variation.”
95As with the Carbon Dioxide laser, the Erbium laser reacts with the water moisture in the skin to create a vaporization
eﬀect. However, the Erbium laser treats the skin in much smaller increments, allowing for ﬁner control of the resurfacing, and
creates much less heat damage than the CO2 laser. This usually allows for faster post-op healing time and faster disappearance
of the red face of healing often seen with resurfacing. The trade-oﬀ may be less wrinkle and scar removal than with the CO2
lasers. See id. A NEW BODY IN ONE DAY, Chapter 15.
15“Used properly ...resurfacing lasers are a useful additional tool in managing patients with disﬁguring prob-
lems such as acne scarring, with a degree of control not previously possible.” 96
2. Tattoo Removal
Lasers which are sensitive to diﬀerent colors are used to remove tattoos97, with diﬀerent lasers being used to
remove the diﬀerent colors of the tattoo98. The lasers used deliver extremely high energy which shatters the
tattoo ink particle or pigment without destroying the surrounding skin. However, although these procedures
have a high rate of patient satisfaction, the side eﬀects sometimes include a change in skin texture or
pigment99.
3. Red Marks on the Face or Body
Lasers can treat vascular or abnormal blood vessels and red birthmarks on the skin surface. A ﬂash lamp
pulsed dye laser is generally used on the most common birthmark, known as a ‘port wine stain birthmarks’
(the Gorbachov birthmark), as well as other red marks100. Eﬀectively, the laser used produces a wavelength
of light which is selectively absorbed by the hemoglobin in the birthmark thereby fading the redness on the
skin 101.
4. Freckles, Moles, Age or Sun Spots and Other Pigment Irregularities
Using a laser that responds to color (usually the Q-Switched Yag and Q-Switched Alexandrite lasers), will
often remove freckles, age spots, moles and other colored marks, as well as fading the appearance of brown
birthmarks (known as caf´ e-au-lait marks)102.
96See supra note 92.
97See supra note 82, A NEW BODY IN ONE DAY, Chapter 15.
98The Q-Switched Yag laser is used to fade red inks, while the Q-Switched Ruby and Alexandrite lasers fade the green colors.
All three lasers can remove the dark blue/black inks. See id. A NEW BODY IN ONE DAY, Chapter 15.
99See id. A NEW BODY IN ONE DAY, Chapter 15. See also David H. McDaniel, M.D, Lasers
in Dermatology, Skinlaser Directory (produced by the Disﬁgurement Guidance Centre in the UK) available at:
http://www.skinlaserdirectory.org.uk/Lasers.htm.
100See id. A NEW BODY IN ONE DAY, Chapter 15.
101See David H. McDaniel, M.D, Lasers in Dermatology, Skinlaser Directory (produced by the Disﬁgurement Guidance Centre
in the UK, available at:
http://www.skinlaserdirectory.org.uk/Lasers.htm.)
102See supra note 82, A NEW BODY IN ONE DAY, Chapter 15.
165. Hair Removal
Apart from for cosmetic reasons, hair removal can be a medical necessity in many cases, such as for skin
graft preparation and for ingrown hairs which cause infections.
In August 1997, the FDA approved the Cynosure Photogenica LPIR, a long-pulse Alexandrite laser which
oﬀers quick and relatively painless laser hair removal103. Lasers are becoming the most convenient, eco-
nomical, and less painful method to remove hair from large sections of the body as well as from the face,
underarms, and bikini areas (especially when one considers the more traditional methods of hair removal
including shaving, depilatories which chemically dissolve hair, waxing, and tweezing).
The primary principle behind laser hair removal is “selective photothermolysis” (literally destruction from
heat caused by light). Lasers can cause localized damage by selectively heating dark target matter in the
area that causes hair growth while not heating the rest of the skin104.
Given the increasing popularity of laser hair removal, many laser manufacturers have sought FDA clearance
for their lasers for this indication. The market is growing so quickly that the FDA cannot maintain an up-
to-date list of all laser manufacturers whose devices have been cleared for hair removal, as this list continues
to change daily 105.
Furthermore, given that laser hair removal is relatively new compared to other laser treatments, the longest
observation period reported in the scientiﬁc literature (as of 1998) is two years. Four out of the seven patients
followed up still had stable hair loss106. Hair follicles are not completely destroyed by laser treatment, and
therefore it is diﬃcult to claim that laser hair removal is permanent; indeed most people will experience
103Andrea James, Hair Removal Methods: Laser Hair Removal Overview, August 2001 (available at:
http://www.quackwatch.com/01QuackeryRelatedTopics/Hair/lasermain.html ).
104See id. For a detailed look at laser hair removal, see Ross EV, Ladin Z, Kreindel M, Dierickx C., Theoretical Considerations
In Laser Hair Removal. Dermatological Clinics 17(2): 333-355, 1999; and Littler CM, Hair Removal Using The Nd:YAG Laser
System, Dermatological Clinics 17(2):401-430, 1999.
105To learn if a speciﬁc manufacturer has received FDA clearance, you can check FDA’s Website at
http://www.fda.gov/cdrh/databases.html under the 510(k) database.
106Laser Hair Removal, Skinlaser Directory produced by the Disﬁgurement Guidance Centre in the UK, available at:
http://www.skinlaserdirectory.org.uk/hairemoval.htm. See also Whitney D. Tope and Maria K. Hordinsky, A Hair’s
Breadth Closer?, Archives in Dermatology 1998; 134:867-869.
17some regrowth within a year107.
6. Dental Treatments
FDA has given clearance for argon and carbon dioxide lasers to activate tooth-bleaching solutions and to
treat gum disease. Several lasers have clearance for hard tissue use on teeth108. In May 1997, FDA cleared
the ﬁrst laser system for treating tooth decay, an erbium YAG laser made by Premier Laser Systems109.
Recently, American Dental Technologies received FDA clearance to market its “PulseMaster” laser for caries
(decay) removal110.
According to studies conducted by the manufacturers, the laser is as safe and eﬀective as a high-speed drill
for removing dental decay and preparing a cavity for a ﬁlling. Furthermore, fewer patients require a local
anesthetic 111.
7. Eye Surgery112
Lasers are also used to remove tissue in eye surgery, including removing tumors and cataracts. Several
manufacturers have lasers cleared for photorefractive keratectomy (PRK) and Laser-Assisted In Situ Ker-
atomileusis (LASIK), two procedures for correcting nearsightedness, farsightedness, and astigmatism. The
laser is used to reshape the cornea and focus images correctly on the retina113.
107See id.
108See supra note 78, CDRH, Laser Facts, May 2001.
109See Premier Laser Systems site at: http://www.premierlaser.com/.
110See American Dental Technologies site at: http://www.americandentaltech.com/PulseMaster.htm>l.
111See supra note 78, CDRH, Laser Facts, May 2001.
112As mentioned in the introduction, the use of lasers in eye surgery presents other issues which are not dealt with here given
the conﬁnes of this paper. The topic is only mentioned brieﬂy for the sake of completeness.
113See supra note 81. For information on laser eye surgery and which lasers have received clearance, see FDA’s Website at:
http://www.fda.gov/cdrh/LASIK.
18D. How does the FDA Regulate Lasers?
It is important to note that the FDA only regulates the sale and marketing of medical devices and does not
regulate physicians or nurses in the practice of medicine or in the use of a device.
Before a laser can be legally sold in the U.S., the company wishing to sell or market the laser must seek
approval from the FDA. Medical lasers, depending on their application, are usually categorized in Class II or
III114 and must have premarket approval or premarket clearance from the FDA prior to marketing for any
indication. The majority of laser manufacturers manage to market their lasers through the substantial equiv-
alence procedure discussed earlier. However, there are two minor exceptions to this. Certain unapproved,
nonsigniﬁcant risk Class III medical devices may be distributed in the U.S. to individual practitioners who
have approval from an Institutional Review Board (IRB) for the investigational clinical use of the device115.
Alternatively, lasers may be distributed to investigators participating in a study under an IDE approved by
the CDRH116 (although various IDE requirements need to be complied with 117).
Generally, as discussed in part I, to gain FDA approval under the PMA process, a laser manufacturer must
present evidence that the laser is reasonably safe and eﬀective for a particular use (or indication”). Once
the FDA approves a particular laser, the manufacturer is allowed to promote the medical use of their laser
only for the speciﬁcally approved indication (as will be discussed later, a physician may nevertheless use the
laser for treatments outside the laser’s approved applications)118.
By way of a further regulatory hurdle, all laser devices distributed for both human and animal treatment
in the U.S. are subject to Mandatory Performance Standards. Laser manufacturers therefore have to meet
the federal laser product performance standard and must submit an initial report to CDRH’s Oﬃce of
Compliance prior to distributing the laser119. This performance standard speciﬁes the safety features and
labeling that all lasers must have in order to provide adequate safety to users and patients, and includes
114The Gray Sheet, Vol.12, No. 46, pp. 9-11 (available at http://www.fdcreports.com/grayout2.shtml -Subscription required.
Last visited March 1, 2002).
115See supra note 81.
116as speciﬁed in 21 CFR 812.
117such as monitoring investigations, maintaining records, making reports, and complying with prohibitions on promotion and
commercialization of investigational devices. See 21 CFR 812. See supra note 81.
118See The Laser Training InstituteTM, FDA Rules (available at: http://www.lasertraining.org/fdarules.htm).
119See 21 CFR 1000-1040.11 and 21 CFR 1040.10 H2II. See supra note 81.
19various technical and service requirements120. A laser product manufacturer must certify that each laser
model has passed a quality assurance test and complies with the performance standard before introducing
the laser into the market. This includes distribution for use during clinical investigations prior to device
approval121.
The company/manufacturer certifying a laser assumes responsibility for product reporting to CDRH122;
record keeping, and notiﬁcation of defects, noncompliances, and accidental radiation occurrences123.
However, as will be discussed later in part III, once the FDA has approved a laser, a doctor may decide to use
that laser for other indications if he/she feels it is in the best interest of a patient. The use of an approved
device for other than its FDA-approved indication is called oﬀ-label use. The FDA does not regulate the
practice of medicine124. Therefore, the FDA does not have the authority to regulate a doctor’s practice and
activities (and therefore cannot regulate what doctors tells their patients; require the patient to be provided
with the patient information booklet from the laser manufacturer prior to treatment; make recommendations
for training or credentialing laser practitioners; nor can the FDA maintain or have access to lists of people
performing laser surgery125).
The FDA does, however, regulate the claims manufacturers assert for their devices. Thus, for hair “removal”
lasers, a manufacturer may not claim that laser hair removal is “permanent”, unless the FDA determines
that there is suﬃcient data to demonstrate such result. Nevertheless, several manufacturers have received
FDA permission to claim permanent reduction, but not permanent removal for their lasers. This means that
although laser treatments with these lasers will permanently reduce the total number of body hairs, they
will not result in a permanent removal of all hair126.
Indeed, in the early 1970s, laser-like devices for hair removal which selectively targeted individual hair follicles
by delivering energy through a wire-thin ﬁberoptic probe were rushed through the market without adequate
120For further details of the FDA Technical and Service Requirements relating to laser power calibrations and service manuals,
see The Laser Training InstituteTM, FDA Rules (available at http://www.lasertraining.org/fdarules.htm).
121See supra note 81.
122Reporting guides and related regulatory information are available from the CDRH website at:
http://www.fda.gov/cdrh/devadvice. See supra note 81.
123as speciﬁed in 21 CFR 1000-1010.
124See CDRH Information Sheet at: http://www.fda.gov/cdrh/lasik/what.htm.
125See id.
126Permanent hair reduction is deﬁned as the long-term, stable reduction in the number of hairs regrowing after a treatment
regime, which may include several sessions. Permanent hair reduction does not necessarily imply the elimination of all hairs in
the treatment area. See supra note 81.
20testing and were illegally marketed by making claims that the treatment was “painless and permanent”127.
Other claims made in relation to hair removal lasers that the FDA have disallowed (in the absence of
published clinical data to substantiate such claims) include the claim that treatment is “painless”, or that
the use of the laser “guarantees 0% regrowth.”128
In 1995, FDA cleared the ﬁrst laser for hair removal in the US, the SoftLightTM Nd:YAG produced by
ThermoLase129. The device was rushed to the market without adequate testing of eﬀectiveness and was
marketed illegally as being “painless and permanent” until the FDA stepped in130. By the time a medical
paper appeared in 1997 which criticized the eﬀectiveness of the laser and observed full regrowth of all hair
in patients, consumers had already spent thousands of dollars on treatments131.
In 1998, ThermoLase was sued by a consumer (in a class action suit) alleging that the company advertised its
SoftLight laser as having a “long lasting” eﬀect knowing that such treatments did not achieve that result132.
The case was later settled. However, following a number of other lawsuits, the company stopped marketing
its SoftLight laser133.
Improvements in laser technology following 1997, together with the publication of clinical observations on
laser safety and eﬀectiveness, have led to improvements in the overall eﬀectiveness of treatment for patients.
E. Other Regulation
Although beyond the scope of this paper, brief mention will be made of other mechanisms available to an
aggrieved consumer.
A laser manufacturer who designs and markets a medical laser that causes injury to a patient may be held
127Andrea James, Hair Removal Methods: Laser History and Current Issues, August 2001 (available at:
http://www.quackwatch.com/01QuackeryRelatedTopics/Hair/lasermain.html).
128See supra note 81.
129See FDA Docket K950019 (5 April 1995).
130For a description of the treatment using this laser, see Andrea James, Hair Removal Methods: Laser History and Current
Issues, August 2001, p.1 (available at:
http://www.quackwatch.com/01QuackeryRelatedTopics/Hair/lasermain.html).
131See id. Andrea James citing Nanni CA & Alster TS, Optimizing Treatment Parameters for Hair Removal Using a Topical
Carbon-Based Solution and 1064-nm Q-Switched Neodymium: YAG Laser Energy, Archives of Dermatology 1997 Dec;133(12):
1546-9.
132Tester v ThermoLase, Calif Superior Court (S.F. County, case #995285).
133See supra note 130.
21liable under general product liability law based on the negligent design or manufacture of the laser; for breach
of an express or implied warranty of safety and/or may be held strictly liable in tort134.
A physician who performs laser treatment resulting in injury to a patient could also be subject to a mal-
practice suit brought by the injured patient based on the tort of negligence (where a technical or judgmental
error has occurred) or based on a lack of informed consent (where a negative result or complication occurs
through no fault or negligence of the doctor)135.
F. Limits on Device Regulations: Pre-emption
Regulation of medical devices, particularly lasers, is arguably severely limited by the doctrine of ‘pre-
emption’. The MDA of 1976 speciﬁcally preempts state laws that are diﬀerent from, or in addition to,
any federal requirement applicable to the device which relates to safety or eﬀectiveness.
The possibility of device manufacturers avoiding state product liability claims on the basis
that such claims are preempted by the FDCA136 is one of the more controversial aspects of
the 1976 MDA. While the result of this may not be so harmful in the case of a device that
has undergone the PMA process, this is not the case where a device avoided the procedure
by relying on the §510(k) substantial equivalence procedure. In such cases, manufacturers of
medical devices would enjoy immunity from state tort claims. Without this fear of lawsuits,
laser manufacturers have arguably less incentive to ensure their laser equipment is safe.
However, the scope of preemption under MDA is unclear following the Supreme Court’s decision in Medtronic,
Inc v Lohr 137where the court held that a 510(k) would not always preempt state tort claims.
Justice Stevens stated that a ﬁnding of substantial equivalence under 510(k) was not a state-
ment by the FDA regarding the safety and eﬀectiveness of a device, but simply permission
to market the device without going through the PMA process. Indeed the CDRH has agreed
with this interpretation: “A ﬁnding of substantial equivalence does not represent, and should
134For an elaboration of this, see John R. Irwin MD, Legal Aspects of Lasers, April 30, 1999 (available at
http://www.lawyerdoctor.com/lasers.htm ).
135See id.
136See Caleb Nelson, Preemption, 86 VA. L.Rev 225 (2000). See the preemption provision in 21 U.S.C. §360k(a).
137518 U.S. 470 (1996).
22not be construed as, a statement of a devices’ safety and eﬀectiveness.”138 However, a majority
of the court believed that the MDA could preempt state tort claims, but that Lohr’s claims
in the case were not preempted.
Unfortunately, the trend after Lohr in the circuit courts is to ﬁnd that both a PMA and a §510(k) submission
has preemptive eﬀect139. Indeed, in the recent case of Kemp v. Medtronic Inc140, the Supreme
Court denied an appeal by an Ohio woman seeking to overturn a lower court ruling that her
state law tort claims were preempted by the MDA. The case involved an allegedly defective
pacemaker, which the FDA had approved for sale pursuant to §510(k).
In the case of laser manufacturers, the beneﬁts of preemption are clear but for consumers unable to sue
under the common law of tort, preemption is an assault on the fundamental right of injured persons to
legal redress. Proponents of federal preemption of state claims, such as the American Medical Association,
argue that product liability claim have a negative impact on the development of new medical technologies
such as lasers141. Nevertheless, as already mentioned, the threat of product liability suits may
act to ensure that device manufacturers exercise a certain level of care when producing their
devices. Indeed, device manufacturers gain a double beneﬁt by avoiding the time, costs and
investment needed for premarket research as to a laser’s safety by using the substantial equiva-
lence procedure, whilst gaining immunity from tort claims based on their devices being unsafe
and defective.
138See LESS THAN THE SUM OF ITS PARTS, supra note 82 at 8.
139See also Buckman Co v Plaintiﬀs’ Legal Committee, 121 S.Ct. 1012 (2001) where it was held that the MDA preempted
state “fraud on the FDA” claims which attempt to recover for injuries suﬀered from devices which would not have obtained
FDA approval if the device manufacturer had not defrauded the FDA during the premarket review process.
140No. 00-1766, cert. denied (U.S., Oct. 1, 2001)
141AMA, Report of the Board of Trustees: Impact of Product Liability on the Development of New Medical Technologies (1
June 1988).
23III CRITICAL CONSIDERATIONS REGARDING LASERS AND THE LASER INDUSTRY
A. Side eﬀects and other considerations of the treatment itself.
Patients are generally warned to avoid prolonged exposure to the sun for a few months after laser treatment.
This is to protect the new layer of skin that is being formed as a result of laser resurfacing, and which is
extremely sensitive142. Furthermore, patients experience bruising and swelling for between 7 and 10 days
after treatment depending on the healing capacity of the individual143. It should be further borne in mind
that the results are not perfect – patients should see an improvement in the skin, but will not have perfect
unlined and unscarred skin.
Unfortunately, darker skinned ethnic groups are not generally suitable candidates as the laser alters the skin
color too unpredictability and dramatically144.
As with all medical procedures, complications are possible with laser surgery, including a prolonged redness
of the skin and pigmentary changes such as hyerpigmentation when the skin appears darker than normal145.
Other more serious risks include permanent hypopigmentation (lighting of the skin) in the area of the
resurfacing, as well as scarring, burns, lesions and infections (especially if the surgeon removes more layers
of skin than necessary or uses an excessively high settings 146). Indeed postoperative infections can be
devastating. Herpes simplex virus infections can also occur resulting in severe scarring147.
The more common problem with lasers, however, is the risk of burning. A recent newspaper report cited
the case of a cosmetic surgeon in Florida who disﬁgured 5 women when a laser he used to remove wrinkles
caused serious burns instead 148.
142In other laser treatments aimed at removing skin discolorations, the skin is also very sensitive following treatment, neces-
sitating the wearing of sun block for at least 6 months after treatment.
143See supra note 78, CDRH, Laser Facts, May 2001.
144See supra note 79.
145See supra note 89, and Alexandra Greeley, FDA Consumer, May-June 2001.
146See Dennis Jacobson MD & Lawrence S. Bass et al, Carbon Dioxide And ER:YAG Laser Resurfacing, Aesthetic Laser
Surgery 27:2, p.241-250 (April 2000); Alexandra Greeley, FDA Consumer, May-June 2001; and Andrea James, Hairfacts:
Lasers, at www.hairfacts.com/medpubs/lasermed.html
(“Skin discoloration which can last several months can occur in 1% to 10% of patients, with a higher likelihood in darker skin”).
147This is why patients most at risk should receive a course of an antiviral prior to the laser treatment. See supra note 148.
148See F. Schulte and J. Bergal, Member Quits Board Of Medicine in Protest, The South Florida Sun-Sentinel, June 7, 2001,
24There have also been reports in the US of patients who have developed severe anaphylactic shock following
laser treatment which indicates the necessity of having resuscitation equipment available in all establishments
using lasers (especially for tattoo removal), and to have staﬀ fully conversant with resuscitation techniques149.
The following horror story, reported in the FDA Consumer Magazine150, serves to illustrate some of the
problems:
“Consider the case of Anne Jones (not her real name) in semi-rural Mississippi, a stay-at-home mom and a
doctor’s wife. Wanting to remove some mild acne scars, she went to a well-respected local plastic surgeon, but
after a ﬁve-month recovery period, Jones realized that something had gone very wrong. He had just burned
my face, she says. It was red, with scar tissue all over, she adds.
Eventually, Jones went for help to an ophthalmologist who had extensive laser knowledge–many ophthalmolo-
gists use lasers for corrective eye surgery. He took one look at her and exclaimed, Oh, I am so sorry this has
happened to you. He told her that the surgeon had been too aggressive and had not used the right settings,
so that her skin had retained too much heat and had been severely burned...
...Two years after her procedure, [Jones] has spent nearly $70,000 for both the initial surgery and subsequent
consultations and corrective surgeries to remove the scarring. She says she has partially reclaimed her life.
But she bitterly regrets undergoing the initial surgery. I will never look right, says Jones. I would never do
this again.
B. Long-Term Eﬀects.
Because laser resurfacing and laser hair removal are new methods, long-term data on safety and eﬀective-
ness have not yet been established. However, a number of studies on laser resurfacing using microscopic
examination have shown that the physical changes that occur to laser-treated skin are essentially identical
to those that occur with either dermabrasion or chemical peel151.
Furthermore, response rates to treatment have not been established; nor have regrowth rates (for hair
14B.
149Dr J A Cotterill BSc MD, The Management Of Tattoos With Lasers, Skinlaser Directory (produced by the Disﬁgurement
Guidance Centre in the UK, available at:
<http://www.skinlaserdirectory.org.uk/Tattoos.htm>.)
150See supra note 79.
151See Plastic Surgery Information Service at:
http://www.plasticsurgery.org/surgery/lasersrg.htm.
25removal treatment) been accurately established and cannot be predicted due to a number of variables152.
Indeed, results of laser treatment vary widely, and despite promotional claims by laser manufacturers, there
is insuﬃcient comparative data to determine if one type of laser is more eﬀective and safer than another 153.
Results of resurfacing are also diﬃcult to quantify. How do you measure improvement? Most studies have
provided only subjective evaluation and no comparative objective data154.
Accordingly, at present time, results can only be reviewed on a short-term basis, which includes evaluating
such criteria as recovery, immediate cosmetic improvements, and complications. Gradually, over the years,
results will need to be looked at on a long-term basis, which will include reviewing the longevity of the
cosmetic improvements, and again, the complications155.
Given that lasers have been rushed to the market without a full evaluation of their capabilities and limitations,
it is important, if not vital, that researchers and practitioners publish their experiences and ﬁndings.
Fortunately, skin cooling and pain management techniques continue to be improved156 although the risks of
side eﬀects have not been eliminated157. Indeed, a consumer death was reported in 2001 due to a combination
of pain medications prior to laser treatment158.
C. Cultural Factors about our Society
As mentioned in the introduction, today, in our consumer-driven and time-demanding culture, for many,
life is about ﬁnding the quickest and easiest way to do something. Lasers oﬀer a ‘quick-ﬁx’ enabling us to
rejuvenate ourselves over a lunch break 159.
Demand and supply for laser treatment has been heavily inﬂuenced by the media. Among the public at
152See Andrea James, Hairfacts: Lasers, at www.hairfacts.com/medpubs/lasermed.html
and See supra note. Also, see id.
153See Raulin C, Greve B, and Raulin S, Ethical Considerations Concerning Laser Medicine, Lasers in Surgery and Medicine
28:100-101 (2001).
154See supra note 146.
155See id.
156See Haas AF, Use of a Unique Cooling Gel Applied Prior to Laser Hair Removal, Surgery. 2000 Nov;26(11):1045-6.
157See supra note 130.
158Jackman T, Man’s Death After Visit to Clinic Spurs Suit, Washington Post, January 31, 2001, p.B1.
159See Michael J.Ward, The History and Controversial Future of Refractive Surgery, SURE Program (1999) (available at
http://www.sciencenet.emory.edu/undergrad/SURE/Articles/1999 art ward.html).
26large, the idea of laser treatment invokes ideas of painless, speedy treatment enabling us to attain beautiful
unblemished skin with little eﬀort. Indeed, thanks to the media, the laser has been given magical powers160.
Many people are convinced by the preliminary ﬁndings that these surgeries are safe and beneﬁcial. Nev-
ertheless, caution must be taken. As already mentioned, there is no long-term data on the eﬀect of lasers.
Nor are there comparable studies that would allow physicians to accurately predict what sort of eﬀect these
surgeries can have forty years from now161.
As one commentator notes:
“the United States has a tendency to immerse itself in medicine that enhances life. Ironically, without proper
testing and enough data, such life-enhancers can prove to be detrimental. Before anyone undertakes such
a procedure whether it is for their eyes, their weight or their hair, they must realistically understand the
implications of their undertaking.”162
Unfortunately, in today’s fast-paced society, most patients do not have the time or energy to do the necessary
homework on the treatment they plan to undergo. As a result, the tendency is to trust the ﬁrst laser physician
a patient encounters. Objectivity is removed and the patient subjects him/herself to a limited perspective.
An example is that of a physician who only uses one type of laser (and spent a great deal of money on it) who
may neglect to inform the patient that another laser has been found to be more eﬀective for the patient’s
condition. Indeed, it is conceivable that some physicians may try to use the one laser they have so heavily
invested in to treat a multitude of cosmetic complaints, which may not be in a patient’s best interests 163.
D. Promotional Claims by Laser Manufacturers and the Need for Clinical Data
The massive public interest in lasers, and the patient’s demand for laser treatment have been fueled by the
media, and more particularly, by eﬀective advertising and marketing from the laser companies. As noted by
laser researcher Christian Raulin, M.D.:
Laser companies, tattoo and cosmetic studios, as well as self-proclaimed laser institutes promote their work
with full-page advertisements in newspapers and lifestyle magazines... It is not uncommon for the industry
160For an interesting discussion on lasers and the media, see Raulin C, Greve B, and Raulin S, Ethical Considerations
Concerning Laser Medicine, Lasers in Surgery and Medicine 28:100-101 (2001).
161Supra note 159.
162See id.
163See id.
27to advertise newly developed lasers for which the eﬃcacy has not been determined by means of objective,
randomized trials. When a laser is ﬁrst marketed, there are thus no dependable data available from studies;
instead, physicians must rely upon the often unfounded claims from the advertising literature. 164
To many physicians, the rapid increase in demand for laser treatment oﬀers a new source of income, as
well as presenting a new pressure for them to buck the trend and to purchase a laser or risk losing out to
competitors.
Unfortunately, however, promotional material from manufacturers and practitioners is often unreliable. It is
common for the industry to advertise new lasers whose eﬀectiveness has not been determined by objective
clinical evidence. When a laser is ﬁrst marketed, there is therefore no dependable date available and thus,
physicians must rely on the unsubstantiated claims in the advertising material165. Self-promotion is also
common among laser practitioners, especially given that they have incurred signiﬁcant expense for a new
laser. The pressure to recoup such expense as well as an attempt to use the one laser for a number of treat-
ments (when other lasers would be more eﬀective) leads to a series of expensive, ineﬀective and, sometimes,
unsafe treatments.
The laser industry is being driven by market forces, with minimum consideration being given to evidence-
based medicine. There is little comparative data to allow physicians and their patients to make rational
choices 166. This has led to the result whereby well-founded scientiﬁc studies are no longer the basis for the
widespread use of lasers. Therefore, as noted by some commentators:
“Careful clinical assessment cannot occur under such conditions, and the absolute opposite of the Hippocratic
Oath to do no damage can easily be achieved. 167
Rox Anderson M.D., one of the pioneers in the ﬁeld of laser dermatology, comments, that there is a big
problem brewing:
164Raulin C, Greve B, Raulin S., Ethical Considerations Concerning Laser Medicine. Lasers in Surgery and Medicine 28:100-
101 (2001).
165See id.
166Laughlin SA, Dudley DK, Long-Term Hair Removal Using a 3-Millesecond Alexandrite Laser, Jour-
nal of Cutaneous Medicine and Surgery (2000) Apr;4(2):83-88. See Andrea James, Hairfacts: Lasers, at
www.hairfacts.com/medpubs/lasermed.html.
167See supra note 164.
28“Unfortunately, there is relatively little good, hypothesis-driven research on lasers in dermatology. These
studies are expensive and slow to perform, analyze, present, and publish. The laser companies are quick to
promote their new devices and procedures, even before eﬃcacy and safety are well established, and before a
speciﬁc FDA clearance is given...
But the problem lies mainly with us, the professionals. We should simply refuse to believe infomercials over
peer-reviewed studies... Those industry salesmen who can’t support their claims well, should be tolerated only
as village idiots. In short, the patients are ours, and we should make better patient care the only real bottom
line.” 168
In a perfect world, the laser would be able to do what its makers claim it will do. However, as one commen-
tator notes:
“today laser salesmen tell you their lasers can do anything: ﬁgure out your taxes, improve your sex life, open
your garage door. Don’t buy this. Claims must be measured against proven performance”169.
The Federal Trade Commission and the Consumer Product Safety Commission, as well as a variety of other
federal agencies, regulate the advertising of medical devices, including lasers, however, whether they can
comprehensively regulate all the claims made by laser manufacturers is open to doubt.
Part of the reason why we have reached this position, is because of the ability of laser manufacturers to avoid
the PMA process by using the substantial equivalence provision. This has led to unfortunate consequences
in the medical laser industry with the majority of new lasers entering the market via this route to the
detriment of the consumer given that in many cases, no clinical data has been submitted to the FDA as
to the laser’s safety and eﬀectiveness. Indeed, focusing on substantial equivalence rather than absolute
safety and eﬀectiveness has led to laser manufacturers to design clinical and pre-clinical tests focusing on the
question of substantial equivalence, rather than proving safety and eﬀectiveness170. Surely, eﬀorts would be
better spent researching absolute safety and eﬀectiveness given that this is the main patient concern 171.
In an interview with Dr Larry Bass172, he notes that most cosmetic lasers today have been marketed via
168Rox Anderson, M.D., Lasers in Dermatology: A Critical Update, Journal of Surgery and Medicine. 2000 Nov;27 (11):
700-5; and Rox Anderson, M.D., Response to Letter to the Editor, Lasers in Surgery and Medicine 28:102 (2001).
169See Barry A. S. Lycka, Shaping a New Image: The Practice of Cosmetic Surgery, Chapter 13 (1st ed. 1999).
170Indeed, the FDAMA reinforces this focus by instructing the FDA to limit its clinical data submission requirements only to
information related to substantial equivalence. See 21 U.S.C. §360c(i)(1)(D) and Richard Cooper etc, see supra note 63.
171See supra note 63, Richard Cooper etc.
172Interview with Dr Lawrence Bass. M.D., F.A.C.S on 31 January 2002 at his New York clinic. Dr Bass is Co-Director of
29the substantial equivalence procedure and not through the PMA process, with the result that no clinical
testing has been done on lasers employing this procedure (laser manufacturers generally not being required
to submit clinical data). Indeed, even on the relatively few occasions when clinical testing on a new laser is
done, and when clinical data has been submitted to the FDA by a laser manufacturer, such data (including
any test results) is generally not made available (either to the public or to practitioners). Larry Bass notes
that most laser manufacturers do not like disclosing such test results for fear of competition.
As will be discussed later, most laser manufacturers are relatively small and specialized compared to other
companies within the medical device industry. Many laser manufacturers obtain funding from venture
capitalists who, as a condition of ﬁnancing, oblige the manufacturer to either repay the loaned funds or
generate minimum revenues within a short-time frame (between 2-5 years). Given such ﬁnancial pressures,
laser manufacturers have a strong incentive to market the device as quickly as possible and to avoid spending
substantial time and incurring costs to engage in clinical studies that would require long-term follow-up (in
any case, most laser companies due to their relatively small size do not have the ﬁnances to fund clinical
research) 173. Indeed, as Larry Bass notes, another important consequence of the lack of clinical testing is
that lasers are not optimized for human application when ﬁrst placed on the market.
E. The Unregulated Use Of Lasers
As mentioned above, the FDA regulates medical devices on the basis of their manufacturing and distribution,
and not on the basis of the use of such devices by physicians. The so-called “practice of medicine” doctrine174,
which provides that the FDA lacks authority to regulate treatment practices by licensed physicians, eﬀectively
allows licensed practitioners to use any legally marketed device for any indication, even if that indication is
not approved speciﬁcally for that device – oﬀ-label use is thus allowed giving the physician a wide latitude
in treatment options175. Signiﬁcantly, the FDA does not distinguish between the oﬀ-label use of drugs and
devices176.
the Center for Minimally Invasive Plastic Surgery at the Institute of Reconstructive Plastic Surgery at NYU Medical Center.
He also currently sits on the Device and Technique Assessment Committee of the Plastic Surgery Educational Foundation and
has served on the Board of Directors of the American Society for Lasers in Medicine and Surgery.
173See id.
174See supra note 56, John J. Smith, Physician Modiﬁcation etc.
175See Buckman Co. v. Pls, Legal Comm., 121 S. Ct. 1012, 1018 (2001): “ ‘Oﬀ-label’ usage of medical devices ...is an
accepted and necessary corollary of the FDA’s mission to regulate in this area without directly interfering with the practice of
medicine.”
176See FDA., 1991 FDA COMPLIANCE MANUAL, No. 7292.900.
30Indeed, the FDAMA explicitly recognized the practice of medicine doctrine by providing that:
“Nothing in this Chapter shall be construed to limit or interfere with the authority of a health care practitioner
to prescribe or administer any legally marketed device to a patient for any condition or disease within a
legitimate health care practitioner-patient relationship”. 177
As Dr. Smith, M.D, Assistant Radiologist at Massachusetts General Hospital, states:
“The practice of medicine doctrine stands ﬁrmly for the proposition that regulatory eﬀorts are directed pri-
marily at device marketing by manufacturers, not device use by physicians. Under the doctrine, a licensed
physician enjoys wide latitude in the treatment use of a physician-modiﬁed product ....” 178
This is particularly signiﬁcant for lasers. Given the cost of lasers, and the fact that such lasers often become
outdated given rapid developments in the area, physicians, only able to aﬀord, one or two cosmetic lasers,
have the incentive to use the lasers for a variety of patient conditions rather than go to the expense of
purchasing a speciﬁc laser that would best treat the patient condition179.
As the FDA does not regulate the practice of medicine, medical practice in the US is generally regulated at
state level via state licensing of healthcare professionals180.
States regulate who can use lasers for various therapeutic procedures. But Class 2 and 3 medical lasers are
prescription devices available for sale only to “licensed practitioners”. It is therefore up to each state to
determine who qualiﬁes as a licensed practitioner, including what training, if any, should be required.
However, inconsistencies occur in the US given that each state’s medical licensing board determines who
qualiﬁes as a licensed practitioner in their state 181. Physicians, electronologists, and beauticians have all
claimed permission to use lasers, but its up to each state to decide182.
177See 21 U.S.C. § 396.
178See supra note 56, John J. Smith, Physician Modiﬁcation etc.
179A reported example of this is the use of lasers designated for the treatment of port-wine stains (red/pink birthmarks) to
treat brown caf´ e-au-lait marks (which generally requires a more speciﬁc laser to remove the melanin produced by a caf´ e-au-lait
mark).
180See 37 Fed. Reg. 16,503 (1972) and the preamble to the Final Rule Regarding New Drug, Antibiotic, and Biologic Drug
Regulations, 52 Fed. Reg. 8803 (1987); Stuart L. Nightingale, Unlabeled Uses of Approved Drugs, 26 Drug Info. J. 141 (1992).
See more generally, supra note 56, John J. Smith, Physician Modiﬁcation etc.
181See supra note 78, CDRH, Laser Facts, May 2001.
182Crawley M.T. & Weatherburn H., Application of Regulations to Cosmetic Lasers in Private Practice, Journal of Radiological
Protection. 2000 Sep;20(3): 315-9.
31More signiﬁcantly, Larry Bass notes that the requirement is only for the treatment to be ‘supervised’ by a
licensed practitioner, and therefore the treatment itself can be performed by anyone without the licensed
practitioner even being present 183. According to reports, many places that oﬀer laser treatment claim that
it is done under the supervision of a physician; however, in some cases the physician may not be on site
when a technician performs the procedure 184.
One of the main areas of concern within the laser industry is the use of lasers by unregulated and unqualiﬁed
‘practitioners’. Indeed, unqualiﬁed people are ﬂooding the cosmetic laser market which, in itself, presents a
grave risk to consumers.
One commentator notes that as with x-ray use 100 years ago, “use of dermatological lasers is in danger of
being rapidly debased into a cosmetic procedure”185. Self-proclaimed “laserologists” have set up “training
institutes” for beauticians and other non-physicians. Some even oﬀering laser treatment to consumers without
direct medical supervision186. The increased availability of lasers to non-physicians will increase the likelihood
of injury and quackery.
As noted by Christian Raulin, MD:
“Anyone, including healers, hair stylists, tattoo artists, and cosmeticians, can buy lasers and then advertise
for their services. There are no legal requirements for training, no quality control measures, no oﬃcial quality
standards of guidelines ...We must demand the extensive scientiﬁc evaluation of new and existing systems;
objective and trustworthy marketing by laser manufacturers; well-founded training for laser operators; and
legislation which restricts the use of lasers to physicians alone.” 187
Indeed, given the investment involved by laser manufacturers in marketing a laser, they are so eager to sell
their lasers that they stage one- or two-day training courses, which has led to the situation that now dentists,
obstetricians, gynecologists, and family doctors are oﬀering laser surgery188.
Unlicensed practitioners cannot assess skin types, nor develop an understanding of how lasers aﬀect the skin.
183See supra note 172.
184See Laura Meade Kirk, “First Razors, Now Lasers”, South Coast Today, 20 April 1999.
185See supra note 130.
186See id.
187Raulin C, Greve B, and Raulin S, Ethical Considerations Concerning Laser Medicine, Lasers in Surgery and Medicine
28:100-101 (2001).
188Tina Alster, M.D., director of the Washington Institute of Dermatological Laser Surgery. See supra note 79.
32In the weekend courses oﬀered by some laser manufacturers, very little practical training is given and no
mention is made of potential complications and how to deal with them189. Instead, as Raulin et al notes,
“hands-on training is performed on apple and orange peels under the guidance of so-called ‘specialists”’190.
According to Richard Felten, a senior reviewer in FDA’s Center for Devices and Radiological Health:
“The person planning to do laser surgery must understand the basic physics of how laser energy is absorbed
by tissue and how tissue responds. Then that person should go where the surgery is performed and watch a
skilled surgeon use the equipment”191.
Ideally, the best people to use lasers are the dermatologists and plastic surgeons who best understand skin
and surgery of the skin.
Indeed, as Tina Alster192 notes:
“sometimes people may choose the wrong laser, or a surgeon may believe more is better, which can lead to
signiﬁcant burning.193
Without an understanding of the basic physics of how laser energy is absorbed by tissue and how tissue
responds, as well as an understanding of dermatology generally, fatal mistakes can be made by an untrained
or rogue laser users.
Accordingly, problems and complications do not generally happen with dermatologists and plastic surgeons,
but occur with nurses, beauticians and other unqualiﬁed users who take crash weekend courses and rent laser
equipment that they are not familiar with (especially where the rental equipment tends to be older and not
tuned up)194.
189See id.
190See id.
191See supra note 79.
192See id.
193See id.
194See Rose Palazzolo, Do You Rent or Own, ABC News, April 18, 2001 (available at:
http://abcnews.go.com/sections/living/DailyNews/laser risks010418.html).
33The American Society of Plastic Surgeons acknowledge a death rate of 1 patient per 57,000 surgeries (not
limited to laser surgeries), and that 0.5% of patients develop serious complications. Some argue that as such
treatment is optional (the patient not being ill or diseased), even this relatively low rate of death or injury
is unacceptable195.
As regards diﬀering state regulation across the US, this also presents a problem, given that residents of
diﬀerent states receive diﬀerent standards of care depending on their state’s credentialing policy for laser
practitioners. Rhode Island, for example, requires that all electrologists be licensed. To obtain a license
they must go to school, serve an apprenticeship for 650 hours, and pass a national exam196. But, like many
states, Rhode Island has no such regulations or licensing requirements for people using lasers and laser-like
devices for hair removal197. In comparison, New Jersey provides that all laser treatments must be performed
by an MD198.
Nevertheless certain states have passed laws relating to the ownership, registration, and use of lasers199.
However, state law varies considerably in this area so that one would need to review the laws of their
particular state.
Furthermore, as physicians must eﬀectively police themselves, the doctor may need to discourage patients
from treatment when such treatment would be detrimental no matter how much the patient wants it. If a
patient has low self-esteem, they may never be happy no matter what you do – they may need counseling
more than surgery200.
Despite the FDA regulating the marketing of lasers for the speciﬁc indications requested, the FDA can
only recommend training needed to operate the lasers. Credentialing is a state function, since states are
responsible for the licensing of doctors and nurses, and standards for laser training vary from state to state.
To date, no national policy exists for credentialing those planning to practice laser surgery201, nor is there
any single agency or authority which provides laser certiﬁcation or credentialing of physicians.
195See Judith Gaines, Body Works, The Boston Globe Magazine, February 6, 2002.
196Laura Meade Kirk, “First Razors, Now Lasers”, South Coast Today, 20 April 1999.
197See id.
198See supra note 172.
199See John R. Irwin MD, Legal Aspects of Lasers, April 30, 1999 (available at http://www.lawyerdoctor.com/lasers.htm ).
200See Body Works, The Boston Globe Magazine, February 6, 2002.
201See supra note 79.
34Despite this, some positive developments have occurred. National Council on Laser Excellence has been
formed to provide voluntary certiﬁcation of laser service engineers, laser operators and laser safety oﬃces
(although this Council does not address the certiﬁcation of physicians)202.
The American National Standards Institute has promulgated a variety of standards with respect to medical
devices. There are currently proposed standards relating to the medical use of lasers203 which, if adopted
uniformly across America, will have signiﬁcant eﬀect on the industry.
A further problem that is unfortunately ignored in the laser industry is that very few clinics have the facilities
to oﬀer a comprehensive care program for patients undergoing laser treatment, including having staﬀ qualiﬁed
in administering general anesthesia or sedating the patient, as well as oﬀering CPR. Nor do many clinics
provide adequate post-operative care, especially to those patients who have extensively damaged skin due
to laser treatment204. Resuscitation equipment should be available in all establishments using lasers, as well
as having staﬀ fully conversant with resuscitation techniques.
A recent story in the Washington Post reported the death of a 20-year old man who suﬀered an allergic
reaction whilst undergoing treatment for laser hair removal. According to the report, at the moment of crisis,
no suitably qualiﬁed doctors were around in the clinic to administer CPR or other lifesaving treatment that
could have saved the patient 205. There have been other reports of severe anaphylactic shock following laser
treatment.
The above story illustrates the dangers of inadequately staﬀed and ill-equipped clinics that provide laser
treatment.
F. The Laser Industry Itself and Financial Pressures: Just Big Business?
Lasers are extremely expensive to own and operate, costing between $30,000 to $250,000 (vision correction
lasers cost $500,000!), and some doctors own several, with up to a million dollars invested in their equipment.
The technology changes so rapidly that in a few short years the equipment becomes outmoded and has to
202See The Laser Training InstituteTM, About Credentialing (available at http://www.lasertraining.org/about.htm ).
203See ANSI Z136.1. See also supra note 194, John R. Irwin MD, Legal Aspects of Lasers.
204See supra note 200.
205Tom Jackman, Man’s Death After Visit To Clinic Spurs Suit, The Washington Post, January 31, 2001, p.B01.
35be replaced.
The costs of buying and operating a laser are enormous. Furthermore, given this expense, most laser
practitioners and clinics can only aﬀord one laser, which necessitates them choosing the “right” laser from a
wide selection of ever-increasing lasers. Unfortunately, there is no “universal laser” that will work for every
condition206, yet once a laser has been purchased, practitioners have a ﬁnancial incentive to use that laser
as often as possible and to treat as many conditions as possible to the detriment of the consumer patient
(especially where alternative treatments would be safer and more eﬀective, as well as less costly)207.
Furthermore, like personal computers, lasers become outdated within a very short time with technical de-
velopments in the ﬁeld taking place daily. As one commentator notes: “before the ﬁrst payment has been
made, there are already better, higher-performance alternatives which are often more expensive that the
earlier models”208. Yet, very few practitioners or clinics have the funds to regularly expand their armory of
lasers. Some clinics rent laser equipment giving them access to the lasers they need. However, this option is
highly impractical. Careful planning and coordination is needed to manage patient appointments and visits.
Further, to be economical, a laser clinic must ensure it has a minimum number of patients to be treated by
a particular laser on the day it rents out that laser, which may encourage the liberal use of the laser for a
variety of conditions outside the laser’s labeled indications209.
Furthermore, given that each laser is unique, those renting lasers will not always be able to attain the detailed
knowledge and signiﬁcant hands-on experience required for each laser. Indeed, being an intermittent laser
surgeon, as one laser researcher puts it, “is like trying to be an electrician on the weekend after taking a
crash course in the past”210.
By way of an example, the cost for a LASIK laser is approximately $2,500 per eye. LASIK is big business
in the American corporate world. Lasers cost approximately $500,000 and run about $90,000 annually in
maintenance costs. One company that produces such equipment called VISX has a market capitalization
of $3.5 billion dollars. This means that all of VISX’s stock is worth this dollar amount. In fact, the recent
206See supra note 159.
207See id.
208See id.
209See supra note 194, ABC News, April 18, 2001.
210Dr. David Goldberg, Director of Laser Research at Mount Sinai School of Medicine (quoted in ABC New Report on April
18, 2001 – see id).
36run-up in VISX’s stock price over the past year combined with the lofty price-to-earnings ratio of 100 that
it carries, suggests that shareholders expect this company to earn a lot of money. For investors to pay such
an expensive price for a stock, indicates that people expect VISX to continue to make as much money in the
future as they have in the past 211.
However, many laser companies are experiencing ﬁnancial troubles. Premier Laser System (mentioned above)
has been experiencing ﬁnancial troubles necessitating it to petition for reorganization under Chapter 11 of
the Bankruptcy Code in March 2000212. Similarly, American Dental Technologies is experiencing falling
revenues and proﬁts213.
Indeed, according to EyeNet Magazine (an oﬃcial journal published by the American Academy of Ophthal-
mology), the LASIK market is experiencing hard times. Large laser eye centers oﬀering discount prices, like
LASIK Vision and Icon Laser Centers, have been experiencing ﬁnancial troubles and have been gradually
reducing the price for laser vision correction, so that in some markets, it costs $500 for treatment. Un-
fortunately, as a result of falling prices due to increased competition within the industry, proﬁts for such
companies and their competitors plummet214. According to industry analysts, times are desperate for many
laser centers215. There are numerous reports of ﬁnancial troubles in the laser industry216.
The pressure to sell lasers has never been so great.
A good example serves to illustrate the problem. According to a report in the Business Journal of Tampa
Bay217, Sunshine Laser Centers Inc, which competed for business in the LASIK procedure, went bankrupt
within a year of joining the market and has ﬁled Chapter 11 bankruptcy protection in U.S. Bankruptcy
Court, Middle District of Florida,
211See Michael J.Ward, The History and Controversial Future of Refractive Surgery, SURE Program (1999) (available at
http://www.sciencenet.emory.edu/undergrad/SURE/Articles/1999 art ward.html).
212See Premier Laser System Press Release at: http://www.premierlaser.com/pressreleases/bankruptcyannouncement.htm.
213See American Dental Technologies Quarterly Report for May 2001 at:
http://biz.yahoo.com/e/010515/adli.html, and ADL’s Income Statement as of September 30, 2001 at
http://biz.yahoo.com/fin/l/a/adli.html.
214See EyeNet Magazine, April 2001 at: http://www.aao.org/eyenet mag/04 01/news.html.
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217Sarah Fanous-Samaan, Business Journal of Tampa Bay, January 12, 2001. See:
http://tampabay.bizjournals.com/tampabay/stories/2001/01/15/story1.html.
37Tampa Division. Court records show that Sunshine estimated its debt between $1 million and $10 million.
Sixty-ﬁve entities and potential creditors were served with notice on December 23 218.
Of signiﬁcance, the Business Journal reports that:
“The Chapter 11 ﬁling spawned speculation that Sunshine succumbed to price competition that requires mas-
sive patient volume to sustain the high overhead of running a LASIK practice.” 219
Dr. Byron E. Holley, who operated at Sunshine Laser as the chief surgeon and medical director, stated that:
[Laser] businesses start up and ...fail. When you see people willing to do it (the LASIK procedure) for $499,
you have to wonder. The business is very money-driven right now. The amount of competition in this area
had to be a factor. We are saturated. 220
Fierce competition surrounds the laser industry. It is a crowded market, and a medical practice is a business.
You have to be proﬁtable to provide care. It is indeed a challenge for all medical practices in today’s
environment. Sunshine’s bankruptcy ﬁling mirrors situations of other health care providers in the business.
Expensive equipment and high overheads (especially given the pre- and post-operative care that is required),
not forgetting the costs of advertising and marketing the laser itself present severe ﬁnancial obstacles to
any company contemplating entering the laser industry. This, combined with the competitive nature of the
industry which has driven down prices (as well as encouraging price slashing) to historically low levels, has led
to increased emphasis on volume and ‘getting patients through the door’. Now consumers are bombarded
with aggressive advertisements, from newspapers and over the airwaves, with claims of better prices and
better surgeons221.
Indeed, given the nature of laser treatment, which unlike other medicine, treats the patients’ subjective self-
image and not objective symptoms of disease, doctors in the ﬁeld wish to ensure the patient is subjectively
happy. With laser treatment, it is not diseased skin which is treated, but rather it is healthy skin which is
damaged on the patient’s request 222. As Dr. Christian Raulin MD et al notes:
218See id.
219See id.
220See id.
221See id.
222See supra note 164, Raulin et al.
38“The inevitable conclusion is that the happiness of the patient, which is of course subjective, becomes the
center of medical attention, as opposed to the goal of restoring and maintaining health in the Hippocratic
sense.” 223
Furthermore, if the patient determines his/her treatment, the doctor arguable becomes a vendor in a business
transaction motivated only by proﬁt and the need to keep the patient happy, at the expense of the doctor’s
ﬁduciary responsibility to the patient224.
Raulin et al pessimistically conclude that:
“If ﬁnancial pressure coerces physicians into treating patients using lasers against their better knowledge or
judgment, they will sell their souls to cosmetics and commerce.”225
CONCLUSION
Unfortunately, as there are no oﬃcial statistics of adverse reactions from laser treatments or of surgeries that
have actually gone wrong due to the fault of the practitioner, it is diﬃcult to get a sense of how signiﬁcant
the problems of laser surgery are.
Certainly, one of this paper’s goals was to highlights the dangers inherent in the unregulated cosmetic laser
industry, and although not speciﬁcally advocating a need for regulation both of the laser industry itself and
of those qualiﬁed to use lasers, this is implicit throughout.
However, one must be careful not to castigate the industry without objective evidence. Properly-tested and
approved lasers, in the right hands, are a fantastic tool to genuinely help both those suﬀering from cosmetic
deformities, as well as those just wanting a little boost to their self-image. It is however, inevitable, that
developing technologies should be subject to proper scrutiny from the FDA, and medical authorities, before
223See id.
224See id.
225See id.
39they are allowed out into the market. The substantial equivalence procedure does not provide this adequate
level of scrutiny.
There is an important need for scientiﬁc evaluation of lasers based on evidence collected from objective third-
party clinical trials over a long-term period. This, together, with established training programs instigated
by appropriate medical boards on a federal basis, and legislation restricting the use of lasers to appropriately
qualiﬁed physicians, should help ensure that the laser becomes a justiﬁably popular and potent tool for the
foreseeable future.
A concluding quote from an expert would be appropriate:
“In good hands, lasers are among the safest, most eﬀective, unique, useful tools we have for treating skin.
When oversold or misused, lasers are just another way of courting disaster. ...The sky is not falling (yet).
But what can be come about the decrepit standards for quality of introducing new aesthetic laser applications?
Somewhat tighter FDA regulation for the 510k process of clearing devices might help. ...But the problem
lies mainly with us, the professionals. We should simply refuse to believe infomercials over peer-reviewed
studies. We don’t have to buy every latest gadget appearing in cosmetic magazines. Those industry salesmen
who can’t support their claims well, should be tolerated only as village idiots ...” 226.
226Dr Rox Anderson MD, Letter to the Editor, Lasers in Surgery and Medicine 28:102 (2001)
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